公开(公告)号：US20100166878A1

公开(公告)日：2010-07-01

申请号：US12613330

申请日：2009-11-05

申请人： KWAN-KYU PARK ,  JI-HYUN PARK ,  KYUNG-HYUN KIM ,  SOO-JUNG KIM ,  WOO-RAM LEE ,  KWANG GILL LEE ,  SANG MI HAN ,  YOUNG-CHAE CHANG ,  JUNG-YOON CHOE ,  KEE-SIK KIM

发明人： KWAN-KYU PARK ,  JI-HYUN PARK ,  KYUNG-HYUN KIM ,  SOO-JUNG KIM ,  WOO-RAM LEE ,  KWANG GILL LEE ,  SANG MI HAN ,  YOUNG-CHAE CHANG ,  JUNG-YOON CHOE ,  KEE-SIK KIM

IPC分类号： A61K35/64 ,  A61P9/10

CPC分类号： A61K35/63

摘要： The present invention provides bee venom which can decrease expression levels of sclerotic factors, inflammatory factors and vascular adhesion factors associated with atherosclerosis, and a pharmaceutical composition comprising the bee venom as an active ingredient for the treatment of the atherosclerosis. When the bee venom was administered to laboratory animal models of atherosclerosis, the total cholesterol and neutral lipid were decreased, high-density cholesterol was maintained or even increased, the expression levels of TNF-α and IL-β as inflammation-associated cytokines were decreased in the blood, the expression levels of fibrosis-associated cytokines and vascular adhesion factors were decreased in the main artery and the heart, the plaque deposition generally caused by the atherosclerosis was decreased, and the expression levels of intercellular adhesion molecules (ICAM) and vascular cell adhesion molecules (VCAM), TGF-β1 and fibronectin as fibrosis-related cytokines were decreased.

摘要翻译： 本发明提供了可以降低与动脉粥样硬化有关的硬化因子，炎性因子和血管粘附因子的表达水平的蜂毒，以及包含蜂毒作为动脉粥样硬化治疗动物成分的药物组合物。 当蜂毒对动物动脉粥样硬化实验动物模型给药时，总胆固醇和中性脂质降低，高密度胆固醇维持甚至升高，TNF-α和IL- 随着炎症相关细胞因子在血液中的降低，纤维化相关细胞因子和血管粘附因子的表达水平在主动脉和心脏中减少，通常由动脉粥样硬化引起的斑块沉积减少，细胞间的表达水平 粘附分子（ICAM）和血管细胞粘附分子（VCAM），TGF-β1和纤连蛋白作为纤维化相关细胞因子降低。